Anne E Laumann

Grants

Grants per year

2004 2021

• 3 Active
• 27 Finished

Grants per year

Search results

• Finished

  Prot #8400-211: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 In Patients with Dermatomyositis

  Laumann, A. E.

  Parexel, Idera Pharmaceuticals, Inc.

  3/14/16 → 3/14/19

  Project: Research project

• Prot #CC-220-SLE-001: A PILOT, PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS OF CC-220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

  Laumann, A. E.

  PPD Development, Celgene Corporation

  4/7/15 → 4/7/19

  Project: Research project

• Prot #X052172: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

  Laumann, A. E.

  Clinipace, Inc., XOMA (US) LLC

  3/19/15 → 3/19/18

  Project: Research project

• Prot #X052171: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients with Pyoderma Gangrenosum

  Laumann, A. E.

  Therapeutics, Inc., XOMA (US) LLC

  3/19/15 → 3/19/18

  Project: Research project

• Efficacy of Ustekinumab (Anti-IL_12/23) followed by Abatcept (CTLA4-lg) for the tretment of Psoriasis Vulgaris

  Laumann, A. E.

  Benaroya Research Institute at Virginia Mason, National Institute of Allergy and Infectious Diseases

  9/1/14 → 10/31/18

  Project: Research project

  • psoriasis
  • relapse
  • interleukin-12
  • drug therapy
  • inflammation

• Prot #NOCOMPOUNDLUP0001: Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers

  Laumann, A. E.

  Janssen Research & Development, LLC

  5/14/14 → 10/1/15

  Project: Research project

• Prot #R668-AD-1225: An Open-Label Study of Dupilumab in Patients with Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials

  Laumann, A. E.

  Parexel, Regeneron Pharmaceuticals, Inc.

  5/5/14 → 5/5/20

  Project: Research project

• Clinical and molecular Characterization of lichen Sclerosus as a Model of Vulvar Epithelial Fibrosis

  Laumann, A. E. & Schlosser, B. J.

  Dermatology Foundation

  7/1/12 → 6/30/15

  Project: Research project

• Prot# CNTO1959PSO2001: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X-PLORE)

  Gordon, K. B., Laumann, A. E. & West, D. P.

  Parexel, Janssen Research & Development, LLC

  5/4/12 → 5/4/15

  Project: Research project

• Prot# I1F-MC-RHAZ: A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Pati

  Amin, A. Z. & Laumann, A. E.

  Parexel, Eli Lilly and Company

  4/30/12 → 11/30/19

  Project: Research project

• Prot#A6261008: A Randomized, Subject and Investigator-Blinded (Sponsor-Open), Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Multiple Doses of PD 0360324 in Subjects with Active Cutaneous Lupus E

  Laumann, A. E.

  Parexel, Pfizer Inc.

  10/21/11 → 10/21/14

  Project: Research project

• Prot# CC-10004-PSOR-009: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis

  Laumann, A. E. & Singri, P.

  INC Research, LLC, Celgene Corporation

  7/14/11 → 7/14/17

  Project: Research project

• Prot#R668-AD-0914: A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients with Moderate-to-Severe Extrinsic Atopic Dermatitis

  Laumann, A. E., Paller, A. & West, D. P.

  Ingenix Pharmaceutical Services, Inc., Regeneron Pharmaceuticals, Inc.

  2/1/11 → 2/1/14

  Project: Research project

• Prot# CC-11050-CLE-002: A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects with Discoid Lupus Erythematosus and Subacut

  Laumann, A. E. & West, D. P.

  Celgene Corporation

  12/8/10 → 12/8/13

  Project: Research project

• PROT# MEL-041509: Phase II Randomized, Double-Blind, Placebo-Controlled, Three-Arm,Dose-Finding, Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis

  Laumann, A. E., Singri, P. & West, D. P.

  OSI Pharmaceuticals, Inc.

  10/7/09 → 10/7/12

  Project: Research project

• Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals with Severe Neurological Disorders

  Laumann, A. E. & West, D. P.

  Georgia Institute of Technology, National Institute of Biomedical Imaging and Bioengineering

  9/30/09 → 8/31/12

  Project: Research project

• Prot# BAP01346: Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy

  Dago, P. L., Laumann, A. E., Martini, M. C. & West, D. P.

  Covance Periapproval Services, Inc., Basilea Pharmaceutica International Ltd.

  5/26/09 → 5/26/12

  Project: Research project

• Tadalafil for the Treatment of Secondary Raynaud's Phenomenon

  Laumann, A. E. & West, D. P.

  Lilly ICOS LLC

  5/19/08 → 5/19/11

  Project: Research project

• A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis

  Laumann, A. E. & West, D. P.

  Bavarian Nordic A/S, National Institute of Allergy and Infectious Diseases

  3/1/08 → 2/28/10

  Project: Research project

• Prot# C-2006-004-03: A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Exploratory Study of the Safety and Efficacy of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis that is Moderate in Severity

  Laumann, A. E., Paller, A. & West, D. P.

  Janssen Research & Development, LLC

  4/2/07 → 4/2/08

  Project: Research project

• Prot: Evaluation of the Moisturizing Properties of a Hyaluronic Acid Based Oral Moisturizer Spray in ICU Intubated Patients

  Laumann, A. E., West, D. P. & Wunderink, R. G.

  Sage Products Inc.

  2/16/07 → 2/16/08

  Project: Research project

• Prot# CTA018-CL-2001-1: A Randomized, Double-Blind, Parallel-Group, 4-Arm, 12 Week Study to Evaluate the Safety and Efficacy of Topically Applied CTA018 vs. Vehicle for the Treatment of Adult Subjects with Chronic Plaque Psoriasis

  Laumann, A. E., Singri, P. & West, D. P.

  Cytochroma Inc.

  8/17/06 → 1/3/08

  Project: Research project

• Prot# SS-0601: TheraGauze Alone and Regranex® Gel 0.01% plus TheraGauze In the Treatment of Wagner Stage I Diabetic Foot Ulcers

  Alam, M., Laumann, A. E. & West, D. P.

  Soluble Systems, LLC

  7/17/06 → 5/31/08

  Project: Research project

• Prot# 04-0-207: A Phase 3, Long-Term, Open Label Study to Evaluate the Safety of Twice Daily Tacrolimus Cream-B 0.1% in the Treatment of Psoriasis

  Laumann, A. E. & West, D. P.

  Astellas Pharma US. Inc.

  6/30/06 → 12/31/07

  Project: Research project

• Prot# ACD3101g: Raptiva® Epidemiologic Study of Psoriasis Outcomes and Safety Events (Response) in Patients with Chronic Moderate to Severe Plaque Psoriasis

  Laumann, A. E., Singri, P. & West, D. P.

  PPD Development, Genentech, Inc.

  1/10/06 → 10/7/11

  Project: Research project